SK bioscience will lead a new Gates Foundation-funded project to build an AI platform that helps vaccine developers decide whether to move into costly Phase III trials. The Research Optimization & Trial Outcome Recommender (ROTOR) platform aims to reduce the uncertainty that plagues vaccine development, where the biological signals that predict protection are often unclear or absent.
The project establishes a global collaboration framework with nonprofit health organization PATH and technology consulting firm Slalom. A separate entity, SK AX, will also contribute to development. Together, the partners will use rotavirus vaccine data from SK bioscience and PATH to train and validate the system before targeting broader vaccine programs and disease areas.
What the platform actually does
ROTOR is not a drug discovery tool. It's a decision-support system that synthesizes clinical, immunogenicity, and scientific datasets generated during vaccine development. The platform applies AI-powered evidence synthesis to surface structured insights that help teams evaluate whether a vaccine candidate should advance to large-scale testing. Over time, SK bioscience expects the platform to become a reusable asset across the global vaccine development ecosystem, particularly for manufacturers in low- and middle-income countries.
Vaccine fields like rotavirus lack validated immune correlates of protection - benchmarks that reliably predict a vaccine will work. Assay results often vary by methodology, so Phase II data alone rarely provides a clear go/no-go signal. Phase III trials require substantial financial resources and years of commitment, which makes the decision to proceed especially high-stakes. ROTOR is designed to inject more objectivity into that process by analyzing far more data points and scientific evidence sources than a human team could manually review.
A growing track record in global health
SK bioscience has deepened its ties with international public health organizations in recent years. The company recently signed a licensing agreement with the U.S. CDC to develop an injectable rotavirus vaccine and entered a separate deal with the Gates Medical Research Institute for a novel RSV antibody therapy. In February, it secured a European Union agency project for a pandemic influenza patch vaccine. The company also maintains active programs on Ebola and cell-culture-based avian influenza vaccines.
The ROTOR project adds a new dimension: building reusable AI infrastructure that could outlast any single vaccine candidate. Jaeyong Ahn, CEO of SK bioscience, said, "This project represents a new approach to reducing uncertainty in vaccine development through AI and enabling more scientific and efficient decision-making. Through this consortium, we aim to drive innovation in vaccine R&D while contributing to improved vaccine access worldwide."
AI investments beyond the consortium
The company has been rolling out AI tools across its own R&D operations, including AI-assisted experimental design systems that identify optimal conditions using accumulated research and manufacturing data. These systems trim development timelines and reduce trial-and-error cycles. SK bioscience is also implementing digital twin technologies to model vaccine processes and further expand its AI for Science & Research capabilities as part of a broader digital transformation strategy.
For the ROTOR platform, the initial focus on rotavirus is pragmatic - SK bioscience and PATH hold relevant data and domain experience - but the architecture is meant to be domain-agnostic. Reusable components will be designed so that other vaccine developers, especially those in LMICs, can adapt the system without building from scratch. The Gates Foundation's backing signals an intent to treat the platform as public health infrastructure, not a proprietary commercial product.
Why this matters for IT and development
ROTOR is a real-world implementation of AI in a high-cost, high-uncertainty domain where model outputs directly influence multimillion-dollar decisions. For developers and data engineers, the technical challenges are substantial: ingesting heterogeneous clinical and immunogenicity datasets, producing interpretable recommendations under uncertainty, and ensuring the system generalizes beyond a single vaccine. The project also highlights how AI roles in biotech are shifting from pure discovery tools to operational decision-support systems - areas where strong data engineering, MLOps, and domain collaboration skills become critical. Professionals who understand how to build and validate these Research-focused AI platforms will find increasing demand across pharmaceutical and global health sectors.
Your membership also unlocks:
